Revenue Up but Consolidated Net Loss, Continued Expansion

Revenue: Consolidated KRW 17.4B (YoY +22.8% from KRW 14.2B)
Operating profit: KRW 0.54B (YoY -59.5% from KRW 1.33B)
Consolidated net loss: KRW 0.26B (vs net profit of KRW 0.97B in prior year) → turned red
Net loss attributable to controlling: KRW 0.12B
Standalone: Revenue KRW 12.8B, OP KRW 1.28B, net profit KRW 0.14B (profitable)
Key subsidiaries (Meditip, Meditip SMO) incurred losses
Acquired 24.84% stake in Curi Bio; equity method loss of KRW 0.58B recognized
Issued KRW 15B convertible bonds; derivative liability of KRW 10.4B
No dividends or share buyback/s cancellation
New businesses: AI big data analysis, non-clinical evaluation platform
Cash and equivalents: KRW 26.2B; sound financial structure